Abstract 3685
Background
The clinical relevance of the host immune system in breast cancer has long been studied. Peripheral blood lymphocytes show a great potential due to the advantages of minimal invasiveness, ease of access and high homogeneity. Peripheral blood lymphocytes consists of varying subpopulations. Each subpopulation of peripheral lymphocytes plays a different part in anti-tumor immunity and thus may have different clinical relevance. However, the related studies have rarely been reported.
Methods
A total of 264 advanced breast cancer patients (ABCs) were consecutively recruited at our center between January 2015 and September 2018. All patients received the conventional regimen for advanced breast cancer. Detection of peripheral blood lymphocytes at baseline was accomplished in all 264 patients with 118 patients having ctDNA detection simultaneously. The median survival was estimated by Kaplan-Meier curve, with difference detection by log-rank test and Cox proportional hazards regression model.
Results
The median follow-up time of the study was 13.0 months. Multivariate analysis confirmed that cytotoxic T cell (CTL) was an independent prognostic factor of PFS (P = 0.024). Pierson correlation analysis showed one and only positive correlation between tumor mutational burden (TMB) and CTL level at baseline (P = 0.015). Furthermore, baseline CTL level was only confirmed in the HER2-positive subgroup (P < 0.001) but not in the HR-positive (P = 0.333) or in the TNBC subgroup (P = 0.322). For the entire cohort, the TMB high (>75%) group had a signifiantly shorter PFS (P = 0.004) than TMB low. In the HER2-positive subgroup, the PFS of the TMB high group was shorter than for the TMB low group (P < 0.001). We further use survival data obtained from the TCGA database as a validation set to confirm our findings. As expected, 24 out of 105 HER2-positive patients with TMB high were found to have shorter PFS than TMB low (HR = 0.2, 95% CI: 0.06∼0.71, P = 0.005).
Conclusions
Pheripheral CTL to total lymphocyte proportion is predictive for PFS in HER2-positive ABCs but not in TNBC or HR positive. Since CTL proportion was found to positively correlate with TMB and high TMB indicates shorter PFS. Thus, the negative prognositc role of CTL was, at least, partly due to the TMB of ABCs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peking University Cancer Hospital-Beijing Cancer Hospital.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3361 - Providing a nurse-led telephone intervention for patients treated with oral anticancer medication: symptom management and adherence monitoring
Presenter: Etienne Minvielle
Session: Poster Display session 3
Resources:
Abstract
3937 - Chronological evaluation of health-related quality of life and physical symptoms in postoperative pancreatic cancer patients up to 12 months
Presenter: Naoko Sato
Session: Poster Display session 3
Resources:
Abstract
5620 - Understanding the patients’ Experiences of Radiation Therapy: A Qualitative Study on Prostate Cancer Patients
Presenter: Sakarias Johansson
Session: Poster Display session 3
Resources:
Abstract
1792 - Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy
Presenter: Aydan Uravylioglu
Session: Poster Display session 3
Resources:
Abstract
2169 - The Meaning of Responsibility – a Secondary Analysis of Patients and Caregivers Calls to an Oncology Emergency Telephone
Presenter: Heidi Jacobsen
Session: Poster Display session 3
Resources:
Abstract
4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Elif Dil
Session: Poster Display session 3
Resources:
Abstract
1981 - Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
Presenter: CESCA PUIGMARTI
Session: Poster Display session 3
Resources:
Abstract
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.
Presenter: Marina Bosch - Damas
Session: Poster Display session 3
Resources:
Abstract
5112 - Symptomatic and toxicity management of cancer patients using a telephone support model led by the oncology nurse
Presenter: Gemma Simó
Session: Poster Display session 3
Resources:
Abstract
1365 - Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Presenter: Xiaole HE
Session: Poster Display session 3
Resources:
Abstract